Clinical trial
Children's Hospital of Chongqing Medical University
Name
2022-380
Description
At present, there is no relevant research focusing on children's acquisition of novel coronavirus antibodies through maternal passive transmission. Therefore, this study assessed the changes of maternal passive transmission of COVID-19 antibodies by monitoring the specific antibodies of COVID-19 in young children; This will lay a foundation for further exploring the risk of COVID-19 infection in children and formulating immune prevention strategies.
Trial arms
Trial start
2022-09-01
Estimated PCD
2023-06-30
Trial end
2024-12-30
Status
Recruiting
Treatment
sars-cov-2 vaccine or infection
Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
Arms:
Control group 1, Control group 2, Control group 3, Experimental group
Size
300
Primary endpoint
SARS-CoV-2 IgG
duration of time over which each participant could be 6-month to 12-month
SARS-CoV-2 neutralizing antibody
duration of time over which each participant could be 6-month to 12-month
Eligibility criteria
Inclusion Criteria:
1. Children aged 0-2;
2. No history of blood transfusion, chemotherapy, or related immunosuppressive therapy; No immune system related diseases;
Exclusion Criteria:
Not willing to participate
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 300, 'type': 'ESTIMATED'}}
Updated at
2023-07-06
1 organization
1 product
1 indication
Product
SARS-CoV-2